RecruitingNCT01884051

Hormonal, Metabolic, and Signaling Interactions in PAH

Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension


Sponsor

Vanderbilt University Medical Center

Enrollment

1,899 participants

Start Date

Sep 1, 2012

Study Type

OBSERVATIONAL

Conditions

Summary

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.


Eligibility

Max Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study examines the hormonal, metabolic, and cellular signaling patterns in people with pulmonary arterial hypertension (PAH) — high blood pressure in the lungs — to understand why the disease develops and why it affects women more often than men. **You may be eligible if...** - You have been diagnosed with idiopathic, heritable, or associated pulmonary arterial hypertension (or are a family member of someone with these diagnoses) - You are generally between 0 and 90 years old (specific sub-studies have narrower age ranges) - You have access to the clinic for testing and can tolerate fasting before some tests (for certain sub-studies) **You may NOT be eligible if...** - You have a different type of diagnosis unrelated to PAH - You exceed the age limits for the specific sub-study - You are unable to fast or travel to the clinic as needed Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01884051


Related Trials